US Europe Expansion Distalmotion is actively expanding its US footprint with ongoing clinical trials and 510(k) submissions for additional indications, alongside plans to ramp up commercial activities in Europe. This signals growing opportunities to engage US and European hospitals, ASCs, and HOPDs for DEXTER adoption and expanded indications.

Clinical Validation Recent trials in cholecystectomy and benign hysterectomy support 510(k) submissions and demonstrate improved procedural fluidity and wristed dexterity. Use these outcomes to position DEXTER as a more capable alternative to traditional laparoscopy and competing robotic platforms in surgical portfolios.

Financing Momentum A $150 million Series G round led by Revival Healthcare Capital, along with leadership changes, indicates strong investor confidence and a push to accelerate US commercial adoption. Leverage this momentum to engage hospital systems with financing or ROI arguments tied to faster deployment.

Competitive Positioning Industry chatter highlights growing competition from J&J Ottava and other major players, underscoring Distalmotion’s need to differentiate on ease of use, portability, rapid setup, and seamless integration with existing OR workflows. Use this to tailor value propositions around clinician-friendly deployment and site versatility.

Global Reach & Partners With global headquarters in Switzerland and a US office in Ohio, plus a broad tech stack and multiple indications in development, Distalmotion is well positioned to target hospital networks, ambulatory centers, and outpatient departments across regions. Focus sales efforts on multinational hospital groups and regional distributors seeking scalable robotic solutions.